Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe

Settlement Allows Eylea Biosimilar Launch As GLP-1 Hits Netherlands

 
• By Dave Wallace
  
Biocon Biologics has struck a further aflibercept deal (Shutterstock)

More from Deals

More from Business